Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Glanzmann's Thrombasthenia
Glanzmann's Thrombasthenia
  • Overview
  • Diagnosing
  • Diagnostic Algorithm

A diagnostic algorithm for patients with Glanzmann’s thrombasthenia

This example algorithm was developed by Novo Nordisk in collaboration with experts and follows the latest treatment guidelines. It is meant to raise awareness of common steps for assessing patients and diagnosing Glanzmann’s thrombasthenia in the emergency department (ED) setting.a

A diagnostic algorithm for patients with Glanzmann’s thrombasthenia

This example algorithm was developed by Novo Nordisk in collaboration with experts and follows the latest treatment guidelines. It is meant to raise awareness of common steps for assessing patients and diagnosing Glanzmann’s thrombasthenia in the emergency department (ED) setting.a


aThe provided example is for discussion purposes only and is not intended to represent a recommended algorithm for actual decision making. This example is for illustrative purposes and does not constitute guidance for medical advice or treatment.

Vial and syringe icon

Learn about a potential treatment option for your patients with Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.

Learn about a potential treatment option for your patients with Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.

Get more information
Get more information
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23HCP00056 August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials